Company intelligence / Profile preview

Hawkeye MRI

Ownership: Private
Development stage: Other

Overview

Hawkeye MRI is developing a novel gadolinium-incorporating nanoparticle platform called Nanobrite™ as an advanced contrast agent for magnetic resonance imaging. The technology aims to provide superior organ imagery with longer vascular dwell time and enable high-quality images even on less advanced MRI machines. The company is currently in preclinical development and has exclusively licensed the technology from Nova TheraNostics Inc., which originated at the University of Washington Medical School

Therapeutic areas: Other
Modalities: NanoparticleDevice (MRI contrast agent)
Industry: Medical Imaging

Partnerships

Nova TheraNostics Inc. (technology licensor)University of Washington Medical School (originator laboratory)

Beyond the preview

Go deeper on Hawkeye MRI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hawkeye MRI.

Explore the full profile